Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...
Source: prnewswire.com